Health Economics›Breast cancer›Metastatic or unresectable disease first-line

Metastatic or unresectable disease first-line

Breast cancer · 18 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pertuzumab and T-DM1 Variant #01	ERBB2	R 105 479	21d	15.2 mo	—	3	R 209 647 PFS proxy	—
nab-Paclitaxel and Trastuzumab Variant #01	ERBB2	R 97 652	28d	~4.2 mo	~25.0 mo	~3	~R 236 722 PFS proxy · indirect	2
THP (Docetaxel) Variant #01	ERBB2	R 80 080	21d	17.5 mo	57.1 mo	3	R 110 020 PFS proxy	6
TCH (Paclitaxel) Variant #01	ERBB2	R 45 618	28d	11.1 mo	—	6	R 142 490 PFS proxy	1
Capecitabine, Bevacizumab, Trastuzumab Variant #01	ERBB2	R 45 084	21d	—	—	~3	~R 111 819 indirect	—
Trastuzumab emtansine monotherapy Variant #01	ERBB2	R 41 405	21d	14.2 mo	—	14	R 579 668 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Trastuzumab Variant #03	ERBB2	R 40 931	28d	10.7 mo	—	6	R 133 118 PFS proxy	1
Lapatinib and Paclitaxel (TL) Variant #01	ERBB2	R 39 513	28d	—	27.8 mo	2	R 79 026 PFS proxy	1
Vinorelbine and Trastuzumab (VH) Variant #01	ERBB2	R 39 320	28d	14.8 mo	—	3	R 61 725 PFS proxy	1
TCyH (Docetaxel) Variant #01	ERBB2	R 35 226	21d	—	—	~13	~R 126 847 indirect	—
Docetaxel and Trastuzumab (TH) Variant #02	ERBB2	R 31 039	21d	12.5 mo	40.8 mo	6	R 101 881 PFS proxy	9
ECH Variant #01	ERBB2	R 30 060	21d	—	25.1 mo	3	R 48 003 PFS proxy	—
ACH Variant #01	ERBB2	R 28 888	21d	—	25.1 mo	3	R 44 487 PFS proxy	—
Capecitabine and Lapatinib Variant #01	ERBB2	R 24 587	21d	~6.8 mo	~21.6 mo	~2	~R 49 173 PFS proxy · indirect	7
Trastuzumab monotherapy Variant #09	ERBB2	R 18 745	42d	—	—	~2	~R 37 490 PFS proxy · indirect	2
Docetaxel and Trastuzumab (TH) and Pyrotinib Variant #01 Partial	ERBB2	R 16 980	21d	24.3 mo	—	4	R 35 117 PFS proxy	1
Paclitaxel and Trastuzumab (TH) Variant #01	ERBB2	R 15 366	21d	13.7 mo	24.0 mo	4	R 28 660 PFS proxy	8
Capecitabine and Trastuzumab (XH) Variant #01	ERBB2	R 15 097	21d	9.9 mo	—	3	R 21 861 PFS proxy	2

18 of 18 regimens shown